Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: Double-blind study of two doses;Granisetron en solution buvable dans la prevention des vomissements chimio-induits de l'enfant: Comparaison en double aveugle de deux posologies

Bulletin du Cancer

Volumn 87, Issue 3, 2000, Pages 259-264

  Mabro, May ^a   Cohn, Richard ^b   Zanesco, Luigi ^c   Madon, Enrico ^d   Hahlen, Karel ^e   Margueritte, Geneviève ^f   Breatnach, Fin ^g   Gentet, Jean Claude ^h   Plouvier, Edouard ⁱ  

^a FOCH HOSPITAL   (France)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Clinica Pediatrica   (Italy)

^d Istituto di Discipline Pediatriche   (Italy)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f Hopital Saint Charles   (France)

^g OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^h TIMONE HOSPITAL   (France)

ⁱ HÔPITAL SAINT JACQUES   (France)

Author keywords

Antiemetics; Chemotherapy; Granisetron; Paediatric

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; GRANISETRON; IFOSFAMIDE; METHOTREXATE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROPHYLAXIS; SUSPENSION; VOMITING; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INFANT; NAUSEA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; INFANT; MALE; NAUSEA; VOMITING;

EID: 0034149939     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Berger AM, Clark-Snow RA. Adverse effects of treatment: nausea and vomiting. In : De Vita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. Lippincott-Raven 5th ed, Philadelphie : 2705-14.
2. Guitteny MA, Pajot C, Chalumeau M, Pein F, Grill J, Hartmann O. Traitement des vomissements induits par la chimiothérapie des cancers chez l'enfant. Arch Pédiatr 1998 ; 5 : 661-8.
3. Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide : fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990 ; 8 : 1063-9.
4. Marty M. On behalf of the Granisetron Study Group : a comparison of granisetron as a single agent with conventional combinaison antiemetic therapies in the treatment of cytostaric-induced emesis. Eur J Cancer 1992 ; 28A (suppl. 1) : S12-S16.
5. Allen JC, Gralla R, Reilly L, Kellick M, Young C. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 1985 ; 3 : 1136-41.
6. Lemerle J, Amaral D, Southall DP, Upward J, Murdoch RD. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 1991 ; 27 : 1081-3.
7. Leclerc JM, Jacobson SJ, Cohn R, Pinkerton CR, Mee D, Cedar E. A double-blind dose-ranging study of IV granisetron in children undergoing highly emetogenic chemotherapy. Proc Am Soc Clin Oncol 1993 ; 12 : 1509 abst.
8. Hählen K, Quintana E, Pinkerton CR, Cedar E. A randomised comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. Eur J Cancer 1993 ; 29A (suppl. 3) : 309-13.
9. Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receving moderately emetogenic chemotherapy : a dose-ranging study. Clin Ther 1995 ; 17 : 38-51.
10. Perez P, Hesketh J, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy : a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998 ; 16 : 754-8.
11. Huc P, Block S, Carlier D, Darloy F, Bonneterre ME, Bleuse JP, et al. pour le Grecno (Groupe de recherche en cancérologie du Nord). Granisétron (per os) comparé à ondansétron (per os) dans la prévention des nausées et vomissements induits par des chimiothérapies moyennement émétisantes. Bull Cancer 1998 ; 85 : 562-8.
12. Mabro M, Kerbrat P. Étude comparative du granisétron per os et de l'ondansétron iv chez des patientes recevant une chimiothérapie pour un cancer du sein. Bull Cancer 1999 ; 86 : 295-301.
13. Gralla JG, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998 ; 16 : 68-73.
14. Miyajima Y, Numata SI, Karayama I, Horibe K. Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol Oncol 1994 ; 16 : 236-41.
15. Craft AW, Price L, Eden OB, Shaw P, Campbell R, Pierce DM. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 1995 ; 25 : 28-32.
16. Jacobson SJ, Shore RW, Greenberg M, Spielberg SP. The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Oncol 1994 ; 16 : 231-5.